 Connection
Marshall Lucia to Risk Assessment
This is a "connection" page, showing publications Marshall Lucia has written about Risk Assessment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.315 |
|
|
|
-
Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 02; 27(1):10080-10085.
Score: 0.086
-
Lucia MS, Bokhoven Av. Temporal changes in the pathologic assessment of prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):157-61.
Score: 0.052
-
Iczkowski KA, Lucia MS. Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):216-22.
Score: 0.047
-
Sakr WA, Lucia MS. Potential pathologic markers for prostate chemoprevention studies. Urol Clin North Am. 2004 May; 31(2):227-35.
Score: 0.029
-
Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol. 2016 12 20; 34(36):4338-4344.
Score: 0.017
-
Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate. 2016 09; 76(12):1120-9.
Score: 0.017
-
Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia MS, Kristal AR. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015 Jun; 1(3):342-9.
Score: 0.016
-
Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol. 2014 Aug; 192(2):379-84.
Score: 0.014
-
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol. 2008 Aug; 180(2):544-7.
Score: 0.010
-
Bansal S, Lucia MS, Wiseman A. A case of polyomavirus-associated nephropathy presenting late after transplantation. Nat Clin Pract Nephrol. 2008 May; 4(5):283-7.
Score: 0.009
-
Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20; 25(21):3076-81.
Score: 0.009
-
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19; 98(8):529-34.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|